紅星美凱龍(01528.HK):控股股東提前終止減持A股計劃
紅星美凱龍(01528.HK)(601828.SH)公布,本月3日收到控股股東及一致行動人士提前終止減持A股計劃,並自1月17日起實施以來未曾減持股份。控股股東原擬由1月17日起計六個月內減持不超過1.306億股。
集團指,紅星控股把6,802.3萬股A股通過大宗交易方式轉讓予紅星控股全資子公司常州美開,涉1.56%股權,轉讓均價為每股5.17元人民幣,設有6個月禁售期,而控股股東及一致行動人士持股由去年12月26日的60.54%降至54.85%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.